The global Radiodermatitis Market is estimated to be valued at US$ 407.2 Mn in 2023 and is expected to exhibit a CAGR of 4.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Radiodermatitis, also known as radiation dermatitis, is a common side effect of radiation therapy for cancer patients. It affects the skin in the area being treated with radiation. Topical steroid therapies have emerged as an effective intervention to prevent and treat radiation-induced skin reactions.
Market Overview:
Radiodermatitis manifests as inflammation and damage to the basal layer of epidermis. It is considered one of the most common side effects of radiation therapy experienced by over 90% of patients. Hydrogel and hydrocolloid dressings, topical corticosteroids, oral mucositis healers are widely used to manage radiodermatitis.
Market key trends:
One of the key trends witnessed in the market is increasing adoption of topical steroid therapies for management of radiodermatitis. Topical steroids are preferred as first line therapy due to favorable safety profile and ability to deliver drug directly at site of action. Also, these agents are readily available in multiple formulations such as cream, gel, ointment allowing convenient once or twice daily application suiting individual patient needs and comfort. Furthermore, clinical studies have demonstrated topical steroids to be as effective as oral steroids in prevention and treatment of radiation-induced dermatitis with minimal systemic adverse effects.
Segment Analysis
The global radiodermatitis market is segmented on the basis of product, application, and end user. The product segment includes topical, dressings, oral medicines and others. Topical segment dominates the global radiodermatitis market as topical products provide quick relief from pain and protect the irritated skin from external factors.
Key Takeaways
The global radiodermatitis market is expected to witness high growth, exhibiting CAGR of 4.3% over the forecast period, due to increasing cancer incidence and surge in the number of cancer patients opting for radiation therapy.
Regional analysis
North America dominates the global radiodermatitis market due to high prevalence of cancer, availability of advanced radiodermatitis treatment options and presence of major market players in the region.
Key players
Key players operating in the radiodermatitis market Growth are Acelity, Inc. (3M), BMG Pharma S.r.l., ConvaTec Group PLC, DermaSciences Inc. (Integra LifeSciences Holdings Corporation), Intermed Pharmaceuticals, Mölnlycke Health Care, Smith & Nephew Plc, Stratpharma AG, Kannalife, Inc., McKesson Corporation.
No comments:
Post a Comment